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Abstract
Background: Invasive pneumococcal disease (IPD) results in high morbidity and mortality globally each year,
although it is a vaccine-preventable disease. This study aimed to characterize the clinical features of IPD in a
pediatric intensive care unit (PICU) in Taiwan. The seven-valent pneumococcal conjugate vaccine (PCV7) was
introduced in the private sector in October 2005. The estimated coverage rate of PCV7 vaccination in 2010 was
45.5 % among children <5 years of age.
Methods: We conducted a retrospective study at a single center in northern Taiwan for invasive pneumococcal
disease in a PICU from 2009 to 2013. Demographic characteristics, clinical courses, serotype, antibiotic susceptibility,
and outcomes were analyzed.
Results: Over the 5-year study period, 2167 patients were admitted to the PICU; 48 (2.2 %) had IPD. There were 29
female and 19 male patients. Their mean age was 3.7 years (range 0.7–12.5 years, with the peak age at 2–5 years;
n = 30, 63 %). Pneumonia was the most frequent type (n = 38, 79 %), followed by meningitis (n = 10, 21 %). In total,
three patients died, all within 72 h after admission; the final diagnoses were all meningitis. Thirty-four children with
pneumonia received chest tube insertion for pleural effusion drainage. Of them, 22 (65 %) finally still underwent
video-assisted thoracoscopic surgery. Eight (17 %) children had hemolytic uremic syndrome, and seven of them
underwent hemodialysis. In total, 37 serotypes were detected; 95 % were covered by PCV13. Serotype 19A was
most common (54 %) overall; however, in those with meningitis, serotype 19 F was most common.
Conclusions: Meningitis is the most severe type of invasive pneumococcal disease in our pediatric intensive care
unit. It may progress rapidly even when subjects are given antibiotics promptly. The most common serotype in
meningitis is 19 F, which is vaccine preventable. Thus, universal mass pneumococcal vaccination is still needed.
Keywords: Hemolytic uremic syndrome (HUS), herd immunity, invasive pneumococcal disease, mortality, pediatric
intensive care unit, pneumococcal conjugate vaccine, serotype 19 F, Streptococcus pneumoniae
Background
Streptococcus pneumoniae is a Gram-positive encapsu-
lated bacterium. It can cause a wide disease spectrum,
from otitis media to sepsis and meningitis [1]. Invasive
pneumococcal disease (IPD) is defined as S. pneumoniae
isolated from sterile sites, such as blood, cerebrospinal
fluid, pleural fluid, or ascites. IPD results in high global
morbidity and mortality each year [2], but it is a vaccine-
preventable disease [3–5]. Its incidence decreased after
the introduction of a seven-valent pneumococcal conju-
gate vaccine (PCV7) in the private sector in Taiwan in
October 2005 [6, 7]. The estimated coverage rate of
PCV7 vaccination was 5.7 % in 2006 and 45.5 % in 2010
among children <5 years of age. PCV13 was introduced
in April 2010, and in 2013, a national catch-up program
was launched in Taiwan to provide government-funded
PCV13 for all children aged 2–5 years [7].
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The symptoms and signs of IPD are related to host
immunity, S. pneumoniae virulence, and the site of
infection [1]. Early recognition and prompt diagnosis
remain challenges. There have been few studies analyzing
the early clinical presentation in severe IPD in children
since the introduction of PCV7 in Taiwan. We designed
this study to characterize the clinical features and out-
comes of IPD in a pediatric intensive care unit (PICU)
under partial PCV immunization.
Methods
Hospital setting
Chang Gung Memorial Hospital is a tertiary care hospital
in northern Taiwan. Chang Gung Memorial Hospital is
the only referral center in Taoyuan County, which has a
population of 2 million people. The PICU is a 29-bed ICU
serving children over 2 months of age. We reviewed the
Chang Gung Memorial Hospital PICU patient database,
which listed the name and diagnosis of every patient ad-
mitted to the PICU between January 2009 and December
2013. The study was approved by the institution review
board (IRB: 100-2984A3).
Clinical features
All children admitted to the PICU of Chang Gung
Memorial Hospital with isolation of S. pneumoniae from
sterile sites (blood, pleural fluid, and cerebrospinal fluid)
were included. We collected data including demographics,
underlying conditions or illnesses, previous hospitaliza-
tions, laboratory data, empiric and definite antimicrobial
agents, requirements for and duration of intensive care,
surgical intervention, final diagnosis, and outcome.
Pneumonia was defined as the presence of 1) radiological
pneumonia plus positive blood culture, 2) S. pneumoniae
isolates from pleural fluid culture, or 3) positive blood
culture plus placement of chest tube for pleural fluid
drainage. We defined meningitis as the presence of
Streptococcus pneumoniae in cerebrospinal fluid or blood
in association with a clinical diagnosis of meningitis [8].
The Glasgow Outcome Scale–Extended Pediatric
Revision (GOS-E Peds) [9] was used for the assessment
of outcome at 3 months after discharge. The GOS-E Peds
uses the following eight-point scale: 1. upper good recov-
ery, 2. lower good recovery, 3. upper moderate disability,
4. lower moderate disability, 5. upper severe disability, 6.
lower severe disability, 7. vegetative state, and 8. death.
Serotyping of S. pneumoniae
Detection of S. pneumoniae was first done in the Chang
Gung Memorial or other hospital. Since October 2007,
IPD has been listed as a notifiable disease in Taiwan [6].
It is mandatory to report IPD cases and for infection
control personnel to deliver the isolated S. pneumoniae
to the Centers for Disease Control, Taiwan (TCDC).
Upon receipt, S. pneumoniae isolates were subcultured
immediately and confirmed by standard microbiological
methods, followed by serotyping using the capsular
swelling method (Quellung reaction) [6]. The final re-
port was faxed to Chang Gung Memorial Hospital.
Statistical analysis
For analysis of serotype distribution, serotypes were
categorized as PCV7 types (4, 6B, 9 V, 14, 18C, 19 F, and
23 F); PCV13 serotypes not included in PCV7 (1, 3, 5,
6A, 7 F, and 19A); and non-vaccine serotypes. Data ana-
lysis was performed using the SPSS software (ver. 21.0;
SPSS, Chicago, IL). Categorical variables were compared
using Fisher’s exact test. Descriptive statistics for con-
tinuous variables, such as laboratory parameters, were
calculated and are reported as the means ± standard
deviation (SD). The Mann–Whitney U-test was used to
detect continuous variables differences between two
groups. Statistical significance was set at p < 0.05.
Results
Epidemiology
Over the 5 years study period, 2167 patients were admit-
ted to the PICU; of them, 48 (2.2 %) had IPD (Table 1).
There were 29 female and 19 male patients; their mean
age was 3.7 years (range, 0.7–12.5 years, with a peak in
age 2–5 years (n = 30, 63 %). Pneumonia was the most
frequent type (n = 38, 79 %), followed by meningitis
(n = 10, 21 %). The mean PICU stay was 11.2 ± 11.9 days;
the mean length of hospital stay was 21.6 ± 14.0 days. In
total, three cases died, all died within 72 h after admission;
the final diagnosis in all was meningitis. The case-fatality
rate was 6.3 %. Most survived and recovered with no
sequelae. However, there were four children with less than
good recoveries (Table 2).
Clinical characteristics
In total, 38 (79 %) patients initially presented with re-
spiratory distress/failure, and all had radiological pneu-
monia; three of them presented initially with GCS ≤12.
Another 10 (21 %) patients presented initially with
altered mental status without radiological pneumonia
and were finally diagnosed with meningitis; eight of
them presented initially with GCS ≤12. Three children
had no apparent preceding upper respiratory tract in-
fection before admission; one of them died. Also, 12
children had seizures during the illness; 10 were diag-
nosed as having meningitis, and the other two as having
septic shock with encephalopathy.
In total, 16 (33 %) patients needed intubation; six were
‘elective’ intubations to protect the airway because of
altered mental status, and 10 were intubated because of
respiratory failure. Also, 34 children with complicated
pneumonia received chest tube insertion for pleural
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Table 1 Clinical features of IPDs in 48 children admitted to our pediatric intensive care unit
Survival (n = 45) Death (n = 3) Total (n = 48) p
Males 18 1 19 1.00
Age (years) 0.18
< 2 9 2 11
2–5 29 1 30
6–17 7 0 7
Received vaccination 11 0 11 1.00
Symptoms and signs1
Fever 45 3 48
Cough and rhinorrhea 43 2 45 0.18
Vomiting without abdominal pain 15 3 18 0.05
Altered mental status 10 3 13 0.02
GCS <12 8 3 11 0.01
Seizure 9 3 12 0.01
Initial laboratory values
WBC count (1000 cells/mm3) 14.7 ± 12.6 4.6 ± 2.1 14.1 ± 12.4 0.16
CRP (mg/L) 243 ± 107 178 ± 84 240 ± 107 0.32
Positive blood culture result 26 3 29 0.27
Disease category 0.01
Pneumonia 38 0 38
Meningitis 7 3 10
Length of hospital stay 22.9 ± 13.4 1.7 ± 1.2 21.6 ± 14.0 <0.01
in PICU 11.8 ± 12.1 1.7 ± 1.2 11.2 ± 11.9 <0.01
WBC white blood cells; CRP C-reactive protein
1All symptoms were at the time of presentation, except seizure, which was during the illness
Table 2 Details of pediatric IPD cases with less than good recoveries
Case Age (years) Gender Initial presentation1 Clinical diagnosis Serotype Vaccinated Outcome
1 1.1 M Status epilepticus Meningitis 6B No Lower severe disability
GCS:E2V2M4
2 6.2 M Respiratory failure Complicated pneumonia HUS 19 A No Upper moderate disability
3 0.7 M Opitoshtonous Meningitis 19 A No Lower severe disability
GCS: E2V3M4
4 1.9 F Altered mental status Meningitis 19 F No Death
GCS: E1V1M2
5 1.2 F Altered mental status Meningitis 23 F No Death
GCS: E3V2M4
6 9.4 F Altered mental status Meningitis + brain abscess Not available No Vegetative state
GCS: E2V2M4
7 4.6 M Altered mental status Meningitis 19 F No Death
GCS: E3V2M6
1All patients had cough and rhinorrhea, with the exception of patients 1 and 5
M male; F female; GCS Glasgow Coma Scale; HUS hemolytic uremic syndrome
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effusion drainage. Of them, 22 (65 %) ultimately under-
went video-assisted thoracoscopic surgery (VATS). Eleven
(23 %) patients (four meningitis and seven pneumonia)
developed unstable hemodynamic status and had to be
given inotropic agents, including dopamine, epinephrine,
milrinone, or norepinephrine. One child (Patient 2,
Table 2) had complicated pneumonia and developed
respiratory failure with mechanical ventilation; this
patient received extra-corporeal membrane oxygenation
(ECMO) support. Unfortunately, he also had a stroke
during his PICU stay, and had a moderate disability at
follow-up. Also, eight (17 %) children had HUS; seven
of them received hemodialysis. All were in the pneumo-
nia group.
Vaccination status, serotype, and antimicrobial resistance
The vaccination status of all children was known; 37 had
not been vaccinated against IPD. A conjugated pneumo-
coccal vaccine had been administered to 11 children
prior to IPD; seven children received PCV7 and four
received PCV13. In those who received PCV7, two chil-
dren suffered from serotype 19A, a 4-year-old female
who received one dose of PCV7 suffered from serotype
6A, and in four children, the serotypes were unknown.
Of those who received PCV13, a 2-year-old female who
received one dose of PCV13 suffered from serotype 6B,
a 2-year-old male who received one dose of PCV13
suffered from serotype 19A, one child suffered from a
non-typeable type, and in one child, the serotype was
unknown. In the meningitis group, no patient had
received a pneumococcal conjugated vaccine. However,
at least 60 % of serotypes of the patients with meningitis
were covered by PCV13 (Table 3).
In total, 37 serotypes were detected; 95 % were covered
by PCV13 (Table 3). Serotype 19A was most common in
our study. In 2009, serotype 14 was isolated in four children
and serotype 19A in two children. In 2010 to 2013, only
one serotype 14 cases was isolated; however, serotype 19A
was isolated in 18 children. In 2012, serotype 15 was identi-
fied. In 2013, one non-typeable strain was identified. We
further divided the patients into meningitis and pneumonia
groups (Table 3); serotype 19 F was most common and was
detected only in the meningitis group, and serotype 19A
was most common type in pneumonia group. In those with
HUS, serotype 14 was isolated in two children, 19A was
isolated in three children, 6B was isolated in one child, and
the serotype was not available in two children.
All patients were initially prescribed vancomycin plus
ceftriaxone. Antimicrobial sensitivity testing was per-
formed in 55 isolates. No resistance was detected against
vancomycin. Only one S. pneumoniae with penicillin
MIC <0.06 μg/mL was detected, and S. pneumoniae with
penicillin MIC >2 μg/mL was detected in 20 % of all iso-
lates. Three cases of S. pneumoniae with ceftriaxone
MIC ≦0.05 μg/mL were detected, and S. pneumoniae
with ceftriaxone MIC ≧2 μg/mL was detected in 16 % of
all isolates; two were isolated from CSF.
Outcomes
Three patients died in this study; all had meningitis. The
prognostic factors for mortality were GCS < 12 (p = 0.01),
seizure (p = 0.01), and vomiting without abdominal pain
(p = 0.05). All of these three patients had the same charac-
teristics; therefore, the data did not permit the use of logis-
tic regression due to the lack of “complete separation.”
Gender, headache, white cell counts, C-reactive protein,
and vaccination status were not significantly associated
with mortality. Children without good recovery (Table 2)
were more frequent in children <2 years (4/11, 36 %) than
those between 2 and 5 years old (1/30, 3 %) or those 6–17
years (2/7, 33 %; p = 0.01).
Discussion
We provide the first detailed description of the severe IPD
in a PICU under partial PCV immunization in northern
Taiwan. In our study, we examined a series of 48 patients
diagnosed with IPD at a tertiary hospital in Taiwan. Pa-
tients with IPD had two distinct types of presentation:
79 % (38/48) had complicated/uncomplicated pneumonia,
presenting as respiratory distress/failure, and the most
Table 3 Demographic characteristics, serotype distribution, and
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23 F 1 1






Survival 7 38 0.01
1 15,2non-typeable
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common serotype in pneumonia was 19A. The other 21 %
(10/48) children had meningitis, presenting as altered
mental status. Of them, three children died within 72 h,
and 19 F was the most common serotype in meningitis.
All three children who died had the same characteristics,
namely GCS <12, seizure, and vomiting without abdom-
inal pain.
Pneumonia was the most common type of IPD in our
series. Our study, like others [3, 6, 10, 11], highlights the
prevalence of serotype 19A after PCV7 was introduced.
This may have been the result of vaccine selection.
PCV7 was introduced to Taiwan in 2005, and the esti-
mated coverage rate of PCV7 vaccination was 45.5 % in
2010 among children <5 years of age. [7]. For those with
pneumonia, all patients showed good recovery except
one child who had moderate disability after dialysis and
ECMO. This may be the result of advances in critical
care medicine over the past decade [12]. Hemolytic
uremic syndrome is one of the most common complica-
tions of necrotizing pneumonia in Taiwan [13–16]. In
our study, seven patients received hemodialysis because
of HUS. In North America, 50 % of pneumococcus HUS
was associated with serotype 19A after the introduction
of PCV 7 [12, 17]; our study showed similar results.
Meningitis was the second most frequent type of IPD
in our study; however, all three children who died had
meningitis. Among those with meningitis, no S. pneumo-
niae penicillin MIC <0.06 μg/mL was isolated, and 20 %
were resistant to Ceftriaxone . Thus, in those with sus-
pected meningitis, empiric antibiotics, such as vancomycin
plus a third-generation cephalosporin, are suggested [18].
We prescribed vancomycin plus ceftriaxone initially, yet
three children still died within 72 h. Kanegaye et al.
reported that 4 h after parental antibiotics, cerebro-
spinal fluid sterilization of pneumococcus might occur
[19]. These findings indicate that the damage caused by
S. pneumoniae infections may not be stopped by eradi-
cating S. pneumoniae.
The three children who died had the same characteris-
tics, namely seizures, GCS <12, and vomiting without
abdominal pain; all of these signs indicate increased
intracranial pressure (IICP). S. pneumoniae not only
results in disruption of the blood brain barrier but also
in neuronal and vascular injury, finally leading to IICP
and diffuse brain ischemia [20, 21]. Early antibiotic use
is essential; aggressive control of IICP is also important.
Adjunctive therapy is an important issue for pneu-
mococcal meningitis [22], patients with meningitis due
to S. pneumoniae who were treated with corticosteroids
had a lower death rate [23].
Serotype 19 F was the most common type in the menin-
gitis group in our study. In adults, serotype 19 F has been
associated with an elevated risk of meningitis and death
[24]. Hsu et al. reported the effects of a pneumococcal
conjugate vaccine on pneumococcal meningitis; it showed
that serotypes 9 V, 14, and 23 F had better herd immunity
than serotypes 4, 6B, 18C, and 19 F [3]. Wei et al. also
reported that for all serotypes included in PCV, except
serotype 19 F, demonstrated a sustained decreasing trend
between 2008 and 2014 in Taiwan [7]. In our study, at
least 60 % of the meningitis serotypes were vaccine-
preventable. None of the children had an underlying ill-
ness; other studies have also shown that most children
with IPD were previously healthy [7]. Thus, universal mass
pneumococcal vaccination is still needed.
Being aged less than 2 years was not a predictor of
mortality, but it may predict those who will not have a
good recovery [10]. In 2013, a national catch-up pro-
gram was launched in Taiwan to provide government-
funded PCV13 for children aged 2-5 years [7]. In 2014,
the Taiwanese government expanded the age group of
children to 1 year of age. In Taiwan, the prevalence of
S. pneumoniae colonization in children was 14.1 %. By
breaking the chain of disease transmission and reducing
the nasopharyngeal carriage rate among children, this
policy may help to protect children less than 1 year old.
This study had some limitations. First, this was a
retrospective, single-center study, and the sample size
was limited. Additionally, the three patients who died
had the same characteristics, so our data could not sup-
port logistic regression analysis due to the absence of
“complete separation”. Second, some patients had re-
ceived antibiotics before admission; these resulted in
false-negative culture results, and some true IPD cases
were likely not included. Polymerase chain reaction
(PCR) would improve diagnostic yield [10]. Third, some
S. pneumoniae serotypes were not available. Taiwan
CDC provides the S. pneumoniae serotype only to the
first hospital reporting IPD; thus, cooperation between
hospitals is needed. Fourth, host immunity is an import-
ant factor for IPD; in Taiwan, the rate of asymptomatic
carriage of S. pneumoniae in children aged 2–5 years
was 19 % [25], and the incidence of IPD among children
aged 2–4 years was 21.1 per 100,000 populations,
strongly suggesting that host immunity plays a key role.
Gaschignard et al. suggested that children with IPD,
particularly those aged >2 years, should undergo im-
munological investigation [26]. We have been perform-
ing immunological investigations since 2012, and we will
report those results in future.
Conclusions
Our study showed a wide spectrum of invasive pneu-
mococcal disease in our pediatric intensive care unit.
Meningitis is the most severe type. Meningitis can pro-
gress rapidly even when subjects are given antibiotics
promptly. The most common serotype in meningitis
was 19 F, which is vaccine preventable. Thus, universal
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mass pneumococcal vaccination is still needed. We
observed replacement of pneumococcal serotypes,
specifically, the prevalence of serotype 19A. Further
study on controlling increased intracranial pressure
caused by S. pneumoniae meningitis is needed.
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